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The recent pandemic by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing Coronavirus disease-
2019 (COVID-19) affects mainly adults and to a lesser extent children. The major route of spread is via droplets where the 
virus is released into the air in the form of droplets by an infected individual during coughing and sneezing. The virus 
primarily infects the respiratory tract epithelium. Its spike protein interacts via ACE-2 receptor and facilitates the entry of 
the virus into the cells by membrane fusion. The activated Cytotoxic T cells and other cells cause an exaggerated 
inflammatory response releasing huge amounts of pro-inflammatory cytokines like interleukins and interferon. Due to this 
surge in the cytokine levels leading to a storm like state, there is significant endothelial injury causing hyper-coaguable state 
and disseminated intravascular coagulation. The common presentation in children include involvement of respiratory system 
leading to pneumonia, severe pneumonia, acute respiratory distress syndrome and rarely multiorgan involvement.  
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Introduction 
The worldwide spread of novel Coronavirus 
disease-19 (COVID-19) has created an unprecedented 
panic among common people as well as the healthcare 
workers. As per the latest data on 18 May, 2020 
WHO reported worldwide 4628903 confirmed cases 
and 312009 deaths1. On same dates in India a total of 
102032 confirmed cases and 3167 deaths had been 
reported2. The spread of this novel virus started as a 
small outbreak in Wuhan, China in December 2019, 
which has now evolved as a pandemic affecting 
individuals of all ages. COVID-19 is caused by a 
respiratory virus named as severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) which 
belongs to coronaviruses family (CoV)3. It affects 
individual of all ages, especially adults and elderly, 
relatively sparing the children. It enters via the upper 
respiratory tract epithelium and causes flu like illness- 
fever cough, sore throat, difficulty in breathing, 
headache, myalgia and gastro-intestinal symptoms. 
Mild symptoms are present in majority of cases, 
however, it can progress to cause severe pneumonia 
requiring oxygen and other forms of respiratory 
support, both invasive and non-invasive support4. The 
disease can progress to cause varied complications 
like Acute Respiratory Distress Syndrome (ARDS), 
septic shock, multiorgan dysfunction, myocardial 
injury and acute kidney injury (AKI)5. This virus has 
similarity with viruses causing Severe Acute Respiratory 
Syndrome (SARS) and Middle East Respiratory 
Syndrome (MERS), whose immune-pathogenesis is 
known6. Because of this peculiar similarity, a possible 
pathogenesis of SARS-CoV-2 has been explained in 
various literatures. Various case reports and case series 
of atypical presentations in children has gained curiosity 
for in-depth understanding of the pathogenesis in 
children. There have been meticulous efforts to 
understand the clinicopathological presentation of this 
disease in children. This review is aimed at highlighting 
various different possible pathophysiological aspects in 
children and the shift of the pathogenesis as new 
literature is evolving.  
 
Virology 
SARS-CoV-2 belongs to the -coronaviruses  
(-CoV) family of enveloped, positive single-stranded 
Ribo-nucleic acid (RNA) viruses which can cause 
respiratory, enteric, hepatic, and neurologic diseases6,7. 
These include hundreds of members that infect 
humans and other animals such as bats, snakes,  
birds, and other3. SARS coronavirus (SARS-CoV)  
and MERS coronavirus (MERS-CoV) also belongs to 
-CoV6. Phylogenetic analysis show that SARS-CoV-2 
shares 79.5% sequence identity to SARS-CoV  
and 50% sequence identity to MERS-CoV8-10.  
—————— 
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SARS-CoV-2 is a round or oval shaped virus with a 
diameter of 60-100 nm and a genomic size of 29.9 kb. 
Its nucleocapsid is buried inside phospholipid bilayers 
and is covered by 2 different types of protein. The 
Spike protein is present in all the viruses of coronavirus 
family giving it crown like appearance and hence the 
name; another Haemaglutinin-esterase protein is 
present in some members of the family. Other proteins 
are Membrane protein (M protein) and Envelope protein 
(E protein)10. Human angiotensin converting enzyme-2 
(ACE–2) receptors facilitates its entry into the cell by 
interacting with the spike protein9,11. These receptors are 
present on cells of human organs including lung, kidney, 
liver, nervous system, and skeletal muscle12. 
 
Epidemiology: Origin and natural host 
SARS-CoV-2 was first isolated from Bronchoalveolar 
lavage fluid of three COVID-19 infected patients from 
Wuhan, China8. Moreover, these are zoonotic viruses 
with bats as the primary natural host13. The possible 
origin of this virus was from seafood market in Huanan, 
China. It has been seen that Pangolin origin CoVs have 
99% similarity with SARS-CoV-214. Animal to human 
transmission of infection is rare, however this 
transmission can occur if the infective dose is very high, 
called the spillover phenomena15. 
 
Mode of transmission and spread 
SARS-CoV-2 is transmitted from person to person 
mainly by respiratory droplets, resembling the spread 
of influenza and other respiratory viruses, and seldom 
by contact transmission. The virus is released into the 
air in the form of tiny droplets by an infected 
individual during coughing and sneezing. These 
droplets loaded with virus can spread upto 1-2 meters 
and can deposit on distant surfaces16. The virus can 
remain viable on surfaces for days in favourable 
atmospheric conditions, but are destroyed in less than a 
minute by common disinfectants like sodium 
hypochlorite, hydrogen peroxide etc17. A healthy 
individual can get infected by coming in direct contact 
with COVID-19 positive individual. Also one can 
acquire infection if the person touches contaminated 
surface with hands and then touches his eye, nose or 
mouth. The incubation period is quite variable with a 
median incubation period of approximately 4 (2-7) 
days and range up to approximately 14 days18,19. The 
exact duration of viral shedding is still not known. 
However, the viral shedding occurs predominantly in 
first week but may persist for few weeks even in an 
asymptomatic individual. The SARS-CoV-2 virus has 
also been isolated from the stool samples and thus 
subsequent transmission via feco-oral route has also 
been hypothesized, but has not been proven till date. 
These stool samples detected the viral ribo-nucleic acid 
(RNA) even after nasopharyngeal reverse-transcriptase 
polymerase-chain-reaction (RT-PCR) was negative20. 
 
Clinical presentation and spectrum of illness 
It infects predominantly adults and elderly with  
co-morbidities. Children are less commonly affected 
by this virus, many reasons have been postulated for 
the same. Among those with COVID-19, children 
comprised just 2% of the diagnosed cases in China21, 
1.2% of cases in Italy22 and 5% cases in the United 
States23. The most common symptoms were cough 
and pharyngeal erythema in 48.5% and 46.2% cases, 
respectively. Other symptoms include fever (41.5%), 
diarrhoea (8.8%), fatigue (7.6%), rhinorrhoea (7.6%) 
and vomiting (6.4%).In children the median age of 
presentation was 7 years24. Among children infected 
with COVID-19, almost 90% cases were asymptomatic 
or had only mild to moderate disease, 5.2% cases had 
severe illness and only 0.6% presented with critical 
illness requiring intensive care unit (ICU) 
admission25. The prevalence of severe and critical 
disease was 10.6% in infants, 7.3% in 1-5 years, 4.2% 
in 6-10 years,4.1% in 11-15 years and 3% in children 
of 16-17 years of age25. During first 5-7 days, children 
with hyper-acute course presented with severe 
hypoxemia and respiratory distress requiring 
ventilatory support. In the more indolent disease 
children with moderate hypoxemia and respiratory 
distress requiring oxygen therapy improved gradually 
over the week. These patients with indolent course 
may have acute worsening in the form of clinical 
deterioration and hyper-inflammation in the second 
week also known as biphasic illness. Thus the 
spectrum of illness caused by COVID-19 includes 
asymptomatic cases to mild upper respiratory illness 
(URI) like symptoms, severe pneumonia, ARDS, multi-
organ involvement, hyper-inflammatory syndromes like 
Kawasaki Disease (KD), KD shock syndrome, Toxic 
Shock Syndrome, and Macrophage activation 
Syndrome26. Varied complications like myocardial 
injury, acute kidney Injury, disseminated intravascular 
coagulation (DIC) and multiorgan dysfunction 
syndrome can also be seen5. Most of the children 
infected with COVID-19 recover in 2 weeks and 
mortality is rare27. 
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Pathogenesis 
SARS-CoV2 virus primarily infects the epithelium 
of upper respiratory tract and further replication may 
occur in lower respiratory tract as well. The spike 
protein interacts via ACE-2 receptor and facilitates the 
entry of the virus into the cells by membrane fusion. 
The viral RNA genome is then released into the 
cytoplasm and is translated into 2 polyproteins and 
structural proteins, this triggers the viral replication 
leading to viremia28. Other entry mechanisms  
includes clathrin-dependent and clathrin-independent 
endocytosis29. In high viral load, replication of virus 
starts in lower respiratory tract especially bronchioles 
and alveoli causing severe pneumonia3. Since many 
other organs also express ACE-2 receptor, hence 
symptoms suggesting other organs involvement may 
also be present30. Due to COVID-19 infection, 
lymphopenia especially decrease in CD4+ and CD8+  
T cells have been reported in adults. The level of fall in 
CD8+ T cells predicts the severity of the illness31. 
However no such findings have been seen in the 
children. A large case series in children demonstrated 
only 3.5% children presented with lymphopenia25. 
These viral antigenic peptides are presented by major 
histocompatibility complex especially MHC-132, and 
then gets recognized by virus-specific cytotoxic T 
lymphocytes (CTLs). Various HLA polymorphisms 
have been seen to be associated with susceptibility to 
SARS-CoV-2 infection such as HLA-B*4601, HLA-
B*0703, HLA-DR B1*120233 and HLA-Cw*080134. 
These peptides stimulate virus-specific B and T cells. 
The SARS-specific IgM antibodies disappear at the 
end of week 12, while the IgG antibody can last for 
long time. The SARS-specific IgG antibodies 
primarily are S-specific and N- specific antibodies35. 
Rapid viral replication induces cellular damage and 
antibody dependent enhancement (ADE), leading to 
aggressive inflammation36. The activated Cytotoxic  
T cells and other cells cause an exaggerated 
inflammatory response releasing huge amounts of 
pro-inflammatory cytokines (IFN-, IFN-, IL-1b,  
IL-6, IL-12, IL-18, IL-33, TNF-, TGFb, etc.) and 
chemokines by effect or immune cells causing 
interstitial inflammation, exudates and severe 
pneumonitis37. The pathological T cells also release 
granulocyte monocyte colony stimulating factor  
(GM-CSF) that attract circulating CD14+ and CD16+ 
monocytes that expresses interleukin, IL-6, which is 
responsible for accelerating inflammatory responses38. 
Although the exact pathogenesis in children is  
not known, this violent cytokine storm triggers a 
systemic inflammatory response causing multiorgan 
involvement, ARDS and shock. Among the studies 
from critically ill patients with ARDS requiring 
mechanical ventilation, it has been observed that in 
spite of managing ARDS adequately there is higher 
mortality in those with COVID-1939. The surprising 
fact is that these patients with ARDS demonstrate a 
relatively spared lung compliance and higher 
alveolar-arterial oxygen gradient as compared to 
conventional ARDS cases40,41. Lung histopathology 
revealed findings of diffuse pulmonary micro-
vascular thrombi which are consistent with these 
ARDS cases suggesting a vascular occlusive cause  
of ARDS as compared to a low compliance cause  
of ARDS. A large autopsy series of COVID-19 
infected patients showed pattern of exudative  
and early proliferative phases of diffuse alveolar 
damage with diffuse thrombosis of the peripheral 
small vessels on histopathological examination42.  
The suggested etio-pathogenesis can be cytokine 
storm leading to significant endothelial injury  
causing hyper-coaguable profile. A study by  
Tang et al. showed that a procoagulant profile was 
observed in severe cases of COVID-19 with elevated 
D-dimer and fibrin degradation products (FDPs) 
levels. It further demonstrated coagulopathy as  
a hallmark finding in severe COVID-19 cases  
with 71.4% of non-survivors having disseminated 
intravascular coagulation (DIC)43.  
 
Atypical presentations associated with COVID-19 
in children 
There are few reports of hyper-inflammatory shock 
like illness in children which is probably due to 
cytokine storm. There were eight children who 
presented with fluid refractory shock requiring 
inotropes like noradrenaline and milrinone. In these 
children, the laboratory parameters showed elevated C 
reactive protein (CRP), erythrocyte sedimentation rate 
(ESR), elevated procalcitonin and high serum ferritin 
levels suggestive of a hyper-inflammatory state44. 
Other inflammatory manifestations in children 
includes Kawasaki disease (KD) like illness (typical 
or atypical), KD shock syndrome45 and cutaneous 
vasculitis chilblain like lesions46. There are various 
reports of KD and toxic shock syndrome (TSS) like 
illness in children from Italy47 and New York City48. 
From India one published case report of KD like 
illness with hyper-inflammatory shock had been 
GUPTA et al.: CLINICO-PATHOGENESIS OF COVID-19 IN CHILDREN 
 
 
267
reported. This report highlights the use of 
Tocilizumab, IL-6 antagonist (under clinical trials) in 
cases not responding to IVIG49. Some of the adult 
reports suggest an immune based response in the form 
of Guillian-Barre syndrome (GBS) associated with 
COVID-19, however no such reports have been 
identified in children50. 
 
Why Children have milder illness than Adults? 
Children have milder illness as compared to adults 
with COVID-19. The exact reason for this is not 
known but a possible explanation can be given owing 
to the characteristics of the immunity in children. 
There could be multiple reasons playing a role in 
decreasing the severity of illness in children. The first 
possibility is that children may have less viral loads as 
compared to adults. It is also hypothesised that  
the epithelial cells may have reduced expression of 
ACE-2 receptors due to immaturity. It is due to the 
fact that ACE-2 receptors are fully expressed on well 
differentiated epithelial cells. The third possibility is 
that children have a stronger innate response and a 
relatively weak adaptive response. The strong innate 
response can be due to the fact that children have 
exposure to influenza and many other viruses due to 
recurrent viral infections. The adaptive response is 
naïve and lacks memory cells like adults, so is unable 
to mount a vigorous inflammatory response. Fourth 
possibility could be the simultaneous presence of 
other viruses which let SARS-CoV-2 virus compete 
with them and limit its growth.  
 
Conclusion 
SARS-CoV-2 is an enveloped RNA virus which 
belongs to the -coronaviruses (-CoV). It has a high 
affinity to ACE-2 receptors in humans. It is transmitted 
mainly by droplets and primarily infects the respiratory 
epithelium. The spectrum of illness caused by  
COVID-19 ranges from asymptomatic cases, mild to 
moderate illness, severe pneumonia, ARDS, multi-organ 
involvement, to hyper-inflammatory syndromes like 
Kawasaki Disease (KD), KD shock syndrome, Toxic 
Shock Syndrome, and Macrophage activation 
Syndrome. Rapid viral replication induces cellular 
damage and aggressive inflammation which causes 
release of myriad of cytokines and chemokines. This 
cytokine storm leads to significant endothelial injury 
causing hyper-coaguable profile culminating into 
widespread thrombi formation44. Children can also 
present with Kawasaki Disease (KD) like illness (typical 
or atypical), KD shock syndrome and cutaneous 
vasculitis and chilblain like lesions. Pediatric population 
overall has a milder clinical course as compared to 
adults. 
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